<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01429792</url>
  </required_header>
  <id_info>
    <org_study_id>ML21779</org_study_id>
    <nct_id>NCT01429792</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 &amp; 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)</brief_title>
  <official_title>A Multi-Center Study Evaluating the Rate of Genotype 1, 2, 3 &amp; 4 Chronic Hepatitis C Patients With Slow Response / Non-rapid Viral Response to Anti-Viral Treatment of Pegasys (Peginterferon Alfa 2a) in Combination With Copegus (Ribavirin)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This multi-center study will evaluate the viral response in patients with chronic hepatitis
      C, genotype 1, 2, 3 &amp; 4 on standard anti-viral treatment with Pegasys (peginterferon alfa-2a)
      and Copegus (ribavirin). Patients will receive weekly subcutaneous Pegasys plus daily oral
      Copegus for 24 weeks (genotype 2 &amp; 3) or 48 weeks (genotype 1 &amp; 4). Patients identified as
      slow responders/non-rapid virological responders will be eligible for an additional 24 weeks
      of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of genotype 1 patients with partial early viral response (pEVR, a 2-log decrement but with detectable HCV RNA at Week 12 of standard treatment)</measure>
    <time_frame>approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of genotype 1 patients with complete early viral response (cEVR, undetectable HCV RNA at Week 12 of standard treatment)</measure>
    <time_frame>approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of genotype 1 patients with pEVR at Week 12 and undetectable HCV RNA at Week 24</measure>
    <time_frame>approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of genotype 2 &amp; 3 patients not achieving rapid viral response (RVR, defined as undetectable HCV RNA at Week 4 of standard treatment)</measure>
    <time_frame>approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of genotype 2 &amp; 3 patients achieving virological response at Week 24 (EOT - end of treatment, defined as undetectable HVC RNA)</measure>
    <time_frame>approximately 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of genotype 4 patients with partial EVR</measure>
    <time_frame>approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of genotype 4 patients with complete EVR</measure>
    <time_frame>approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of genotype 4 patients with pEVR at Week 12 and undetectable HCV RNA at Week 24</measure>
    <time_frame>approximately 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">940</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa-2a [Pegasys]</intervention_name>
    <description>standard treatment, subcutaneously weekly</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin [Copegus]</intervention_name>
    <description>standard treatment, orally daily</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, &gt;/= 18 years of age

          -  Serologic evidence of chronic hepatitis C, genotype 1, 2, 3 or 4 by anti-HCV antibody
             test

          -  Documented pre-treatment HCV RNA quantitative result

          -  Compensated liver disease (Child-Pugh Grade A)

          -  Patient receiving standard combination treatment of Pegasys (peginterferon alfa-2a and
             Copegus (ribavirin)

        Exclusion Criteria:

          -  Decompensated liver disease (Child-Pugh Class B or C cirrhosis)

          -  Co-infection with active hepatitis A and/or hepatitis B

          -  History or evidence of a medical condition associated with liver disease other than
             HCV

          -  Signs and symptoms of hepatocellular carcinoma

          -  History of poorly controlled thyroid disease, elevated TSH or any clinical
             manifestations of thyroid disease

          -  Therapy with antineoplastic treatment &lt;/= 6 months prior to study day

          -  Diabetes mellitus in subjects receiving an insulin therapy

          -  Evidence of severe retinopathy

          -  Pregnant or breast-feeding women, and male partners of women who are pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ashdod</city>
        <zip>77444</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bat Yam</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beer Sheva</city>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beer Sheva</city>
        <zip>84105</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>33394</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <zip>95146</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nahariya</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nazareth</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rishon Lezion</city>
        <zip>75299</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Safed</city>
        <zip>13110</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <zip>64353</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <zip>67891</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tiberias</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zerifin</city>
        <zip>6093000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2011</study_first_submitted>
  <study_first_submitted_qc>September 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2011</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 22, 2017</submitted>
    <returned>October 10, 2017</returned>
    <submitted>December 20, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

